Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa
- PMID: 19274531
- DOI: 10.1080/02713680802710692
Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa
Abstract
Purpose: To evaluate and report the effectiveness, visual, anatomical, and clinical outcome of intravitreal bevacizumab (Avastin) injection in patients with retinitis pigmentosa (RP).
Methods: Our prospective study included 13 eyes of 7 patients (4 women and 3 men) in the age range of 25-69 years (mean 44.14 years) with cystoid macular edema (CME) secondary to RP. Intravitreal bevacizumab at a dose of 1.25 mg/0.05 ml was injected via a 28-gauge needle. The response rate to treatment was monitored functionally by visual acuity assessment and anatomically using the optical coherence tomography.
Results: The baseline mean central macular thickness was 370.15 microm (range 245-603 microm. The central macular thickness decreased to 142.53 microm (range 124-168 microm) after bevacizumab injections. The pre- and post-treatment visual acuity ranges were 5/400-20/100 and 20/200-20/63, respectively.
Conclusions: Our data reveal that intravitreal bevacizumab administration is effective for the treatment of CME in RP. Further studies with a larger population and longer follow-up period are warranted to assess the efficacy of the treatment.
Similar articles
-
Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.Retina. 2008 Oct;28(8):1053-60. doi: 10.1097/IAE.0b013e318176de48. Retina. 2008. PMID: 18779710
-
Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.Retina. 2006 Nov-Dec;26(9):999-1005. doi: 10.1097/01.iae.0000247165.38655.bf. Retina. 2006. PMID: 17151486 Clinical Trial.
-
Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.Retina. 2008 Feb;28(2):212-9. doi: 10.1097/IAE.0b013e3181619bee. Retina. 2008. PMID: 18301025
-
The effect of an intravitreal dexamethasone implant for cystoid macular edema in retinitis pigmentosa: a case report and literature review.Ophthalmic Surg Lasers Imaging Retina. 2014 Mar-Apr;45(2):160-4. doi: 10.3928/23258160-20140131-03. Epub 2014 Feb 7. Ophthalmic Surg Lasers Imaging Retina. 2014. PMID: 24506098 Review.
-
Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa - a first case report and short review of the literature.BMC Ophthalmol. 2015 Apr 30;15:44. doi: 10.1186/s12886-015-0033-z. BMC Ophthalmol. 2015. PMID: 25925748 Free PMC article. Review.
Cited by
-
Retinal Angiomatous Proliferation in a Patient with Retinitis Pigmentosa.Genes (Basel). 2023 Jul 13;14(7):1438. doi: 10.3390/genes14071438. Genes (Basel). 2023. PMID: 37510342 Free PMC article.
-
Anatomical and functional correlates of cystic macular edema in retinitis pigmentosa.PLoS One. 2022 Oct 21;17(10):e0276629. doi: 10.1371/journal.pone.0276629. eCollection 2022. PLoS One. 2022. PMID: 36269735 Free PMC article.
-
Management of Cystoid Macular Edema in Retinitis Pigmentosa: A Systematic Review and Meta-Analysis.Front Med (Lausanne). 2022 May 16;9:895208. doi: 10.3389/fmed.2022.895208. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35652079 Free PMC article.
-
Retinal cell transplantation in retinitis pigmentosa.Taiwan J Ophthalmol. 2021 Dec 6;11(4):336-347. doi: 10.4103/tjo.tjo_48_21. eCollection 2021 Oct-Dec. Taiwan J Ophthalmol. 2021. PMID: 35070661 Free PMC article. Review.
-
Knockout of CaV1.3 L-type calcium channels in a mouse model of retinitis pigmentosa.Sci Rep. 2021 Jul 26;11(1):15146. doi: 10.1038/s41598-021-94304-3. Sci Rep. 2021. PMID: 34312410 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
